临床肝胆病杂志2017，Vol.33Issue(6)：1173-1178,6.DOI:10.3969/j.issn.1001-5256.2017.06.034
胆汁酸相关非酒精性脂肪性肝病发病机制及其药物治疗的研究进展
Research advances in the pathogenesis of bile acid-related non-alcoholic fatty liver disease and related pharmacotherapy
张敏 1黄明星 2郭列军3
作者信息
- 1. 解放军第三O二医院青少年肝病诊疗与研究中心,北京100039
- 2. 中山大学附属第五医院,广东珠海519000
- 3. 罗格斯大学环境与职业健康研究所,美国新泽西州皮兹卡塔韦08854
- 折叠
摘要
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become a new health issue in the world due co its increasing incidence rate,and in particular,nonalcoholic steatohepatitis is progressive and has poor prognosis.Therefore,there is an argent need to search for the methods for the prevention of disease progression and treatment.Bile acid,as an important metabolite and signal molecule,can adjust the metabolism of lipids and carbohydrates and energy balance inside and outside the liver.Bile acid interacts with is receptors,such as the farnesoid X receptor and Takeda G-protein coupled receptor 5,bile acid transporter,and gut microbiota and is involved in the pathogenesis of NAFLD and nonalcoholic steatohepatitis at different levels.This article summarizes the research advances in the pathogenesis of bile acid-related NAFLD and related pharmacotherapy.关键词
脂肪肝/胆酸类/受体,G-蛋白偶联/综述Key words
fatty liver/cholic acids/receptors, G-protein-coupled/review分类
医药卫生引用本文复制引用
张敏,黄明星,郭列军..胆汁酸相关非酒精性脂肪性肝病发病机制及其药物治疗的研究进展[J].临床肝胆病杂志,2017,33(6):1173-1178,6.
